Financial Times US Pharma and Biotech Summit

Securing the future: Disrupting the pharma business model

14 May 2019 | Convene - 605 Third Avenue | New York

This industry-leading event brings together executives from the world’s largest pharmaceutical and biotechnology companies, their health care providers and health insurers counterparts, technology providers, and other major organizations across the life sciences and health care value chain to review trends and opportunities for creating a successful industry economy.

Disruption is the new normal of the pharma landscape. The advent of cell and gene therapies along with advanced analytics in drug development and diagnostics are also providing enough thrust to this growing market. Executives from across the industry are set to come together at the FT US Pharma and Biotech Summit to discuss the opportunities brought on by these trends, drug pricing in the United States, potential of the personalized medicine market, evolution of digital therapeutics, transformation of pharma business models, and much more.

Visit the FT’s summit page for more information on speakers.

25 percent registration discount

(Use code Deloitte25 when registering)

To register for the summit and learn about the speakers, agenda, and topics, visit:

Issues to be addressed at the FT US Pharma and Biotech Summit:

  • Drug pricing in the US
  • Delivering on the potential of personalized medicine, advanced cell and gene therapies
  • Disrupting the pharma business model
  • Digital therapeutics
  • A new era of patient-owned data and what does it mean for pharma?
  • Advances in analytics
  • Investor forum

Key speakers:

  • Jack Bailey, President, US Pharmaceuticals, GlaxoSmithKline
  • Amy Abernethy, Principal Deputy Commissioner, U.S. Food & Drug Administration (FDA)
  • Bill Sibold, Executive Vice President, Sanofi Genzyme
  • Johanna Mercier, Head of U.S. and Large Markets, Worldwide Commercial, Bristol-Myers Squibb
  • Barbara Tardiff, Head, Bioinformatics, Verily Life Sciences
  • Vipin Gopal, Chief Data and Analytics Officer, Eli Lilly
  • Julie Schiffman, Vice President of Customer Analytics, Pfizer
  • Paul Bleicher, CEO, OptumLabs
  • Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
  • Michael Sherman, Chief Medical Officer and Senior Vice President for Health Services, Harvard Pilgrim Health Care 
  • Michael Ryan, SVP, Worldwide Value, Access, Policy and Health Economics and Outcomes Research, Bristol-Myers Squibb 
  • Ron Philip, Chief Commercial Officer, Spark Therapeutics 
  • Martin VanTrieste, President and CEO, Civica RX
  • Adam Koppel, Managing Director, Bain Capital Life Sciences 
  • Neal Batra, Principal, Deloitte